Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness. (ASI-2012)

February 11, 2014 updated by: Dr. Peter Zahradka, University of Manitoba

The ASI Non-Invasive Arterial Stiffness Screening Device (ASI Device) is an investigational device under development for the non-invasive assessment of arterial stiffness. The ASI Device is considerably smaller and more cost effective than its commercially available counterparts. As the device is readily portable, it is intended to be targeted for use in the community (or at home), as opposed to within the hospital or clinic setting only. However, as the device is still under development, it is not known whether it is capable of determining arterial stiffness with the same sensitivity and consistency as those already in commercial use. An added variable is the fact the sensor for the ASI Device is located on the fingertip.

Validation is a prerequisite for obtaining Health Canada approval of devices for diagnostic purposes. The ASI Device has not been tested against other instruments capable of providing similar measurements. Therefore, a clinical trial to compare the ASI Device against similar devices is necessary. The study will compare measurements of arterial stiffness and other central haemodynamic parameters obtained with the ASI Device against similar measurements from devices that have already been approved for this purpose by Health Canada/United States Food and Drug Administration (FDA).

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This is an exploratory, proof of concept, open sequential registration comparative study designed to establish the utility and accuracy of the ASI Non-Invasive Arterial Stiffness Screening Device (ASI-Device) for the non-invasive vascular assessment of arterial stiffness relative to other such devices already approved and commercially available in Canada and the United States.

The pressure exerted from the contraction of the heart creates a wave form, which travels down the individual's arterial trunk to all parts of the body. The velocity (speed) at which this wave form travels can serve as an indicator of the degree of arterial stiffness. The faster the speed of travel of the pulse wave the stiffer the arteries. It has been demonstrated in other studies that the contour (shape) of the waveform can be affected by the pulse wave velocity and that analysis of this shape is an acceptable surrogate for determining the pulse wave velocity and ultimately determining the severity of arterial stiffness. This method of analysing the contour of the pulse wave to determine the severity of arterial stiffness is called pulse wave analysis (PWA).

The ASI Device non-invasively measures the severity of arterial stiffness derived through pulse wave analysis. The study will compare measurements of arterial stiffness and other central haemodynamic parameters, as derived through pulse wave analysis obtained with the ASI Device, against similar measurements from the SphygmoCor Px System from AtCor and the CR-2000 CV Profiler from Hypertension Inc, devices that already have approval for this purpose by Health Canada and/or the United States Food and Drug Administration.

Three groups of individuals will be sought;

  1. Healthy participants (n=25)
  2. Persons with Type 2 Diabetes and/or Obesity (n=15)
  3. Persons with a diagnosed Cardiovascular/Vascular disease (such as CAD or PAD) (n=15)

Participants will be asked to provide written informed consent prior to participation in the study. Eligible participants will be asked to attend an in-person visit where they will undergo the non-invasive vascular testing. Testing will be comprised of:

  1. Pulse Wave Analysis using the ASI Device
  2. Pulse Wave Analysis using the SphygmoCor Device
  3. Pulse Wave Analysis using the CR-2000 CV Profiler

Although pulse wave contour analysis (PWA) has been demonstrated to be an acceptable surrogate for the assessment of arterial stiffness, Pulse Wave Velocity has been the gold standard for the assessment of arterial stiffness. As such, the VP-1000, a non-invasive vascular screening device, will also be used to measure pulse wave velocity.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • St. Boniface General Hospital - Asper Clinical Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Participants of the Healthy Group must meet the following criteria to be eligible for participation in the study:

  1. Healthy male or female, greater or equal to 20 and less than or equal to 70 years of age;
  2. Willing to comply with the protocol requirements;
  3. Willing to provide informed consent.

Participants of the Obese/Type 2 Diabetes Group must meet the following criteria to be eligible for participation in the study:

  1. Male or female, greater or equal to 20 and less than or equal to 70 years of age;
  2. Presence of clinically diagnosed Type 2 Diabetes, and/or a body mass index (BMI) > 30;
  3. Willing to comply with the protocol requirements;
  4. Willing to provide informed consent.

Participants of the Vascular Disease Group must meet the following criteria to be eligible for participation in the study:

  1. Male or female, greater or equal to 20 and less than or equal to 70 years of age;

  2. Documented evidence of atherosclerosis as manifested by one of the following:

    1. documented myocardial infarction;
    2. documented CAD as defined as >70% stenosis of an epicardial coronary artery;
    3. documented PAD including those with claudication as defined by an ankle brachial index of <0.9;
    4. angiographically documented carotid or lower limb stenosis of >50%
  3. Willing to comply with the protocol requirements;
  4. Willing to provide informed consent -

Exclusion Criteria:

Participants of the Healthy Group will be excluded if they have any of the following:

  1. Presence of a clinically diagnosed disease affecting the circulatory, respiratory, immune, skeletal, urinary, muscular, endocrine, digestive, nervous or reproductive system that requires medical treatment;
  2. Cigarette/cigar smoking, current or within the last 6 months;
  3. Current (within the last 30 days) bacterial, viral or fungal infection;
  4. Taking any prescribed medication (with the exception of birth control or HRT) within the last 3 months or over-the-counter medication within the past 72 h;
  5. Pregnancy;
  6. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.

Participants of the Obese/Type 2 Diabetes Group will be excluded if they have any of the following:

  1. Documented evidence of atherosclerosis as manifested by one of the following:

    1. documented myocardial infarction;
    2. documented CAD as defined as >70% stenosis of an epicardial coronary artery;
    3. documented PAD including those with claudication as defined by an ankle brachial index of <0.9;
    4. angiographically documented carotid or lower limb stenosis of >50%
    5. having had a documented previous intervention for CAD or PAD.
  2. Cigarette/cigar smoking, current or within the last 6 months;
  3. Current (within the last 30 days) bacterial, viral or fungal infection;
  4. Taking over-the-counter medication within the past 72 h;
  5. Pregnancy;
  6. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.

Participants of the Vascular Disease Group will be excluded if they have any of the following:

  1. Cigarette/cigar smoking, current or within the last 6 months;
  2. Current (within the last 30 days) bacterial, viral or fungal infection;
  3. Taking over-the-counter medication within the past 72 h;
  4. Pregnancy;
  5. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.
  6. Having had a documented previous intervention for CAD or PAD

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SCREENING
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: ASI Device
Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
Device: ASI Device
Other Names:
  • ASI Non-Invasive Arterial Stiffness Screening Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To compare the ability of the non-invasive ASI Device to determine arterial stiffness as compared to SphygmoCor, CR-2000 CV Profiler and VP-1000.
Time Frame: 1 day
The average, median, and standard deviation of outcomes from PWA (i.e. augmentation index, or equivalent stiffness index), will be calculated and a correlation analysis conducted to compare the results obtained from each instrument.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Manitoba

Collaborators

St. Boniface Hospital
Arterial Stiffness Incorporated

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (ACTUAL)

July 1, 2013

Study Completion (ACTUAL)

September 1, 2013

Study Registration Dates

First Submitted

November 2, 2012

First Submitted That Met QC Criteria

November 5, 2012

First Posted (ESTIMATE)

November 6, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

February 12, 2014

Last Update Submitted That Met QC Criteria

February 11, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • B2012:040

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on ASI Device

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe